Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 833899
                    [Title] => Novartis cancer drug gets Phl FDA approval
                    [Summary] => 
The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
                    [DatePublished] => 2012-08-02 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 779855
                    [Title] => Novartis, NKTI tie up to help GEP NET patients
                    [Summary] => 
Novartis Oncology has formed an alliance with the National Kidney and Transplant Institute (NKTI) to help improve the diagnosis and management of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs), a form of cancer frequently difficult to diagnose and treat or manage.
                    [DatePublished] => 2012-02-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 700713
                    [Title] => Novartis partners with TMC to enhance  gastrointestinal stromal tumor mg't
                    [Summary] => 
Research-based health care company Novartis has partnered with The Medical City (TMC) to enhance the diagnosis and treatment of gastrointestinal stromal tumor (GIST) in the country.
                    [DatePublished] => 2011-06-30 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

DR. JOSEPH TOVERA

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 833899
                    [Title] => Novartis cancer drug gets Phl FDA approval
                    [Summary] => 
The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
                    [DatePublished] => 2012-08-02 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 779855
                    [Title] => Novartis, NKTI tie up to help GEP NET patients
                    [Summary] => 
Novartis Oncology has formed an alliance with the National Kidney and Transplant Institute (NKTI) to help improve the diagnosis and management of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs), a form of cancer frequently difficult to diagnose and treat or manage.
                    [DatePublished] => 2012-02-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 700713
                    [Title] => Novartis partners with TMC to enhance  gastrointestinal stromal tumor mg't
                    [Summary] => 
Research-based health care company Novartis has partnered with The Medical City (TMC) to enhance the diagnosis and treatment of gastrointestinal stromal tumor (GIST) in the country.
                    [DatePublished] => 2011-06-30 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Novartis cancer drug gets Phl FDA approval

August 2, 2012 - 12:00am

The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast...

Science and Environment

Novartis, NKTI tie up to help GEP NET patients

February 23, 2012 - 12:00am

Novartis Oncology has formed an alliance with the National Kidney and Transplant Institute (NKTI) to help improve the diagnosis and management of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs),...

Science and Environment

Novartis partners with TMC to enhance gastrointestinal stromal tumor mg't

June 30, 2011 - 12:00am

Research-based health care company Novartis has partnered with The Medical City (TMC) to enhance the diagnosis and treatment of gastrointestinal stromal tumor (GIST) in the country.

Science and Environment